In pre-clinical models, BPC 157 has been observed to: Upregulate vascular endothelial growth factor (VEGF) , promoting new blood vessel formation in damaged tissue Modulate nitric oxide (NO) synthesis pathways, influencing vascular tone and healing cascades Interact with the growth hormone receptor system , potentially amplifying downstream tissue repair signaling Demonstrate cytoprotective effects along the gastrointestinal tract its native home territory as a gastric peptide Exhibit apparent neuroprotective properties in rodent models of CNS injury BPC 157 stability in gastric acid unusual for peptides has made it a focus of GI mucosal repair research
Published syntheses have also leaned positive
NEW YORK, June 10 Use of GLP-1 drugs for diabetes or obesity early in the first trimester of pregnancy, before a woman realises she is pregnant, is not a cause for alarm, a large new data analysis suggests
This article examines what semaglutide is, why natural versions don't exist, and evidence-based alternatives that may support your body's natural GLP-1 activity
10.1007/s00204-017-2100-0 29 BaszczykA.AugustyniakA.SkolimowskiJ